O

Owkin pricing

No price is published for the enterprise product, but the structure around it is. K Navigator is free to academic researchers, currently in beta with a waitlist and a stated evaluation period. K Pro is sold to biopharma through a demo and a license, with a three year AstraZeneca agreement named as an example and a published distribution partner program for organizations that want to resell it; the company also describes strategic working sessions run in house with pharma teams and trial periods of stated length, so a buyer can see the shape of an engagement before contact.

Pricing terms

How Owkin pricing works

Pricing model
Free academic tier for K Navigator, in beta with a waitlist and a stated evaluation period; enterprise licensing for K Pro through a demo, with a distribution partner program. No rate card published.

No figure, unit of charge or tier structure is published for K Pro. The license basis (per seat, per program or per skill), what the trial period includes, and the terms of the academic tier once beta ends are not stated.

Compared on price

Owkin pricing against its alternatives

Published prices for Owkin and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.

All Owkin alternatives →

  • O
    Owkin
    Free for academic researchers (K Navigator), not published for K Pro
  • B
    BenchSci
    Free limited academic access; custom enterprise pricing
  • B
    Bioptimus
    No published price
  • C
    Causaly
    Pro $99 monthly; Intelligence $149 monthly
  • E
    Edison Scientific
    Free academic usage, $200 per Kosmos run at launch, enterprise quoted separately
  • I
    insitro
    Not applicable
  • N
    Nabla Bio
    No published price
  • A
    A-Alpha Bio
    No published price
  • I
    IQVIA
    No published price
Questions

Owkin pricing, answered

How much does Owkin cost?

No price is published for the enterprise product, but the structure around it is. K Navigator is free to academic researchers, currently in beta with a waitlist and a stated evaluation period.